Literature DB >> 25305077

OCRL-mutated fibroblasts from patients with Dent-2 disease exhibit INPP5B-independent phenotypic variability relatively to Lowe syndrome cells.

Rodrick Montjean1, Rifdat Aoidi1, Pierrette Desbois1, Julien Rucci1, Michaël Trichet1, Rémi Salomon2, John Rendu3, Julien Fauré3, Joël Lunardi3, Gérard Gacon1, Pierre Billuart1, Olivier Dorseuil4.   

Abstract

OCRL mutations are associated with both Lowe syndrome and Dent-2 disease, two rare X-linked conditions. Lowe syndrome is an oculo-cerebro-renal disorder, whereas Dent-2 patients mainly present renal proximal tubulopathy. Loss of OCRL-1, a phosphoinositide-5-phosphatase, leads in Lowe patients' fibroblasts to phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2) accumulation, with defects in F-actin network, α-actinin distribution and ciliogenesis, whereas fibroblasts of Dent-2 patients are still uncharacterized. To search for mechanisms linked to clinical variability observed between these two OCRL mutation-associated pathologies, we compared dermal fibroblasts from independent patients, four affected by Dent-2 disease and six with Lowe syndrome. For the first time, we describe that Dent-2 fibroblasts with OCRL loss-of-function (LOF) mutations exhibit decrease in actin stress fibers, appearance of punctate α-actinin signals and alteration in primary cilia formation. Interestingly, we quantified these phenotypes as clearly intermediate between Lowe and control fibroblasts, thus suggesting that levels of these defects correlate with clinical variations observed between patients with OCRL mutations. In addition, we show that Lowe and Dent-2 fibroblasts display similar PI(4,5)P2 accumulation levels. Finally, we analyzed INPP5B, a paralogous gene already reported to exhibit functional redundancy with OCRL, and report neither differences in its expression at RNA or protein levels, nor specific allelic variations between fibroblasts of patients. Altogether, we describe here differential phenotypes between fibroblasts from Lowe and Dent-2 patients, both associated with OCRL LOF mutations, we exclude direct roles of PI(4,5)P2 and INPP5B in this phenotypic variability and we underline potential key alterations leading to ocular and neurological clinical features in Lowe syndrome.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25305077     DOI: 10.1093/hmg/ddu514

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  16 in total

Review 1.  The 5-phosphatase OCRL in Lowe syndrome and Dent disease 2.

Authors:  Maria Antonietta De Matteis; Leopoldo Staiano; Francesco Emma; Olivier Devuyst
Journal:  Nat Rev Nephrol       Date:  2017-07-03       Impact factor: 28.314

Review 2.  Phosphoinositides in the kidney.

Authors:  Leopoldo Staiano; Maria Antonietta De Matteis
Journal:  J Lipid Res       Date:  2018-10-12       Impact factor: 5.922

3.  Incomplete cryptic splicing by an intronic mutation of OCRL in patients with partial phenotypes of Lowe syndrome.

Authors:  Eiji Nakano; Amine Yoshida; Yudai Miyama; Tomoo Yabuuchi; Yuko Kajiho; Shoichiro Kanda; Kenichiro Miura; Akira Oka; Yutaka Harita
Journal:  J Hum Genet       Date:  2020-05-19       Impact factor: 3.172

4.  A case of Dent disease type 2 with large deletion of OCRL diagnosed after close examination of a school urinary test.

Authors:  Yaeko Motoyoshi; Tomoo Yabuuchi; Kenichiro Miura; Motoshi Hattori; Koji Kiyohara
Journal:  CEN Case Rep       Date:  2022-01-31

5.  Effects of Proximal Tubule Shortening on Protein Excretion in a Lowe Syndrome Model.

Authors:  Megan L Gliozzi; Eugenel B Espiritu; Katherine E Shipman; Youssef Rbaibi; Kimberly R Long; Nairita Roy; Andrew W Duncan; Matthew J Lazzara; Neil A Hukriede; Catherine J Baty; Ora A Weisz
Journal:  J Am Soc Nephrol       Date:  2019-11-01       Impact factor: 10.121

6.  Digenic mutations of human OCRL paralogs in Dent's disease type 2 associated with Chiari I malformation.

Authors:  Daniel Duran; Sheng Chih Jin; Tyrone DeSpenza; Carol Nelson-Williams; Andrea G Cogal; Elizabeth W Abrash; Peter C Harris; John C Lieske; Serena Je Shimshak; Shrikant Mane; Kaya Bilguvar; Michael L DiLuna; Murat Günel; Richard P Lifton; Kristopher T Kahle
Journal:  Hum Genome Var       Date:  2016-12-08

Review 7.  The oculocerebrorenal syndrome of Lowe: an update.

Authors:  Arend Bökenkamp; Michael Ludwig
Journal:  Pediatr Nephrol       Date:  2016-03-24       Impact factor: 3.714

8.  A 3D Renal Proximal Tubule on Chip Model Phenocopies Lowe Syndrome and Dent II Disease Tubulopathy.

Authors:  Sindhu Naik; Andrew R Wood; Maté Ongenaert; Paniz Saidiyan; Edo D Elstak; Henriëtte L Lanz; Jan Stallen; Richard Janssen; Elizabeth Smythe; Kai S Erdmann
Journal:  Int J Mol Sci       Date:  2021-05-19       Impact factor: 5.923

9.  Transcriptome analysis of neural progenitor cells derived from Lowe syndrome induced pluripotent stem cells: identification of candidate genes for the neurodevelopmental and eye manifestations.

Authors:  Hequn Liu; Jesse Barnes; Erika Pedrosa; Nathaniel S Herman; Franklin Salas; Ping Wang; Deyou Zheng; Herbert M Lachman
Journal:  J Neurodev Disord       Date:  2020-05-11       Impact factor: 4.025

10.  Modeling the neuropsychiatric manifestations of Lowe syndrome using induced pluripotent stem cells: defective F-actin polymerization and WAVE-1 expression in neuronal cells.

Authors:  Jesse Barnes; Franklin Salas; Ryan Mokhtari; Hedwig Dolstra; Erika Pedrosa; Herbert M Lachman
Journal:  Mol Autism       Date:  2018-08-15       Impact factor: 7.509

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.